COYA THERAPEUTICS INC

COYANASDAQ

🏆 #4021 by market capEarnings Nov 10US Equity

$1,002.32▲ $18.84 (+1.88%)

Simulated price

🔔

Track COYA

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 1.9%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$118M

Small Cap

📈Revenue Growth (YoY)

+123.6%

High Growth

📊Gross Margin

99.9%

High

💵FCF Margin

-170613.5%

Thin

⚖️P/S Ratio

14.8x

Expensive

Otter Score

Fair

No chart data available for COYA.

Trading Snapshot

Day Range: $986.43 – $1,021.89
52-Week Range: $3.71 – $7.75
Volume: $3.86B
Avg Volume: $4.34B
Shares Outstanding: 23.5M
Next Earnings: Nov 16, 2026

Fundamentals Snapshot

Annual Revenue: $8M
Last Q Revenue: $243,745
P/E Ratio: -4.7
P/S Ratio: 14.8x
EPS (TTM): $-0.92
Dividend Yield: 0.00%
Dilution (1yr): +2.3%

Why Investors Own COYA

✓High-growth profile — revenue up +27.6% YoY with expanding US Equity exposure.
✓Healthy economics — 78% gross margin and 14% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

COYA THERAPEUTICS INC

COYA

Financial Trends

Revenue

$8M▲ +123.6% YoY

Gross Margin

99.7%▼ −142.6% YoY

Operating Income

−$20M▲ +17.5% YoY

Free Cash Flow

−$11M▲ +4.4% YoY

Shares Outstanding

16.7M▲ +2.3% YoY

Net Cash

$47M▲ +$8M YoY

StockOtter · stockotter.space

About COYA THERAPEUTICS INC

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.

🦦